Study of Bitopertin in Participants With EPP or XLP (APOLLO)

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 4, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

November 30, 2026

Conditions
Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)
Interventions
DRUG

Placebo

Oral dose, once a day for 24 weeks

DRUG

DISC-1459

Oral dose, once a day for 24 weeks

Trial Locations (15)

2050

RECRUITING

Royal Prince Alfred Hospital, Camperdown

3050

RECRUITING

The Royal Melbourne Hospital, Parkville

10029

RECRUITING

Mount Sinai Hospital, New York

27157

RECRUITING

Wake Forest University, Winston-Salem

33146

RECRUITING

University of Miami Miller School of Medicine, Miami

43215

RECRUITING

Remington-Davis Clinical Research, Columbus

44195

NOT_YET_RECRUITING

The Cleveland Clinic, Cleveland

48202

RECRUITING

Henry Ford Health System, Detroit

77550

RECRUITING

University of Texas Medical Branch, Galveston

92647

RECRUITING

Marvel Clinical Research, Huntington Beach

94143

RECRUITING

University of California San Francisco, San Francisco

98195

RECRUITING

University of Washington, Seattle

02115

RECRUITING

Massachusetts General Hospital, Boston

02135

RECRUITING

MetroBoston Clinical Partners, Boston

T6G 2G3

NOT_YET_RECRUITING

University of Alberta, Edmonton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Disc Medicine, Inc

INDUSTRY

NCT06910358 - Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Biotech Hunter | Biotech Hunter